American pharmaceutical company Eli Lilly has broken ground on a $6.5bn Houston factory that will make Foundayo (orforglipron), the company’s first synthetic oral GLP-1 variant for treatment of type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results